The study of nanoparticles has grown in significance during the last several years. Nanoparticles are a kind of material that is composed of very tiny particles. Nanoparticle characteristics vary greatly depending on their size and form. The surface of a nanoparticle significantly affects its optical, mechanical, magnetic, and other characteristics. Nanoparticles are categorised according to their size, origin and chemical composition. We created nanoparticles using both top-down and bottom-up techniques. In this article, we discuss various different methods for creating nanomaterials, such as sol-gel processes, gas condensation, vacuum deposition and vaporisation, chemical vapour deposition and condensate, mechanical attrition, chemical precipitation, electrodeposition, and chemical vapour condensation. When it comes to creating nanoparticles, green synthesis is one of the most effective approaches. In this article, we explore eco-friendly techniques for manufacturing alloy nanoparticles, silver, gold, silver oxide and silver sulphide. We also explore the process by which microorganisms in this setting produce nanoparticles. Size and form must be maintained under certain conditions. We consider ways in which to enhance the production of nanoparticles in the future. The risks posed by nanoparticles and the ways in which to mitigate them were also taken into account.

Benzimidazole-based pyrrole/piperidine analogs (1–26) were synthesized and then screened for their acetylcholinesterase and butyrylcholinesterase activities. All the analogs showed good to moderate cholinesterase activities. Synthesized compounds (1–13) were screened in cholinesterase enzyme inhibition assays and showed AChE activities in the range of IC₅₀ = 19.44 ± 0.60 µM to 36.05 ± 0.4 µM against allanzanthane (IC₅₀ = 16.11 ± 0.33 µM) and galantamine (IC₅₀ = 19.34 ± 0.62 µM) and varied BuChE inhibitory activities, with IC₅₀ values in the range of 21.57 ± 0.61 µM to 39.55 ± 0.03 µM as compared with standard allanzanthane (IC₅₀ = 18.14 ± 0.05 µM) and galantamine (IC₅₀ = 21.45 ± 0.21 µM). Similarly, synthesized compounds (14–26) were also subjected to tests to determine their in vitro AChE inhibitory activities, and the results obtained corroborated that all the compounds showed varied activities in the range of IC₅₀ = 22.07 ± 0.13 to 42.01 ± 0.02 µM as compared to allanzanthane (IC₅₀ = 20.01 ± 0.12 µM) and galantamine (IC₅₀ = 18.05 ± 0.31 µM) and varied BuChE inhibitory activities, with IC₅₀ values in the range of 26.32 ± 0.13 to 47.03 ± 0.15 µM as compared to standard allanzanthane (IC₅₀ = 18.14 ± 0.05 µM) and galantamine (IC₅₀ = 21.45 ± 0.21 µM). Binding interactions of the most potent analogs were confirmed through molecular docking studies. The active analogs 2, 4, 10 and 13 established numerous interactions with the active sites of targeted enzymes, with docking scores of −10.50, −9.3, −7.73 and −7.8 for AChE and −8.97, −8.2, −8.20 and −7.6 for BuChE, respectively.

Nanoparticles (NPs) are at the forefront as they are providing unprecedented solutions to obstacles and issues in treating neurodegenerative diseases. Due to their size, surface characteristics, and ability to be functionalized, these carriers can directly deliver therapeutics across what is considered one of the main barriers to central nervous system (CNS) treatment, the blood-brain barrier (BBB). Through nano-technology, anti-disease agents such as Alzheimer’s, Parkinson’s, and Huntington’s therapies become more bioavailable, specific in action, and with fewer side effects. The NPs serve as molecular carriers that facilitate transport across the BBB by receptor-mediated transcytosis or by disruption of the barrier with a view to properly delivering drugs to the neural tissues. Some of the therapeutic applications of nanotechnology also present the concept of molecular medicine since the NPs are designed to deliver drugs in accordance with specific biomolecule signals. Besides the therapeutic applications, NPs replace the traditional contrast media for magnetic resonance imaging (MRI) and positron emission tomography (PET) scans for better diagnosis as well as disease tracking in the early stages. In addition, their effects on solubility increase the therapeutic potential of earlier useless compounds, and the preservation of bioactive molecules from degradation increases the therapeutic capacity of medications. Neurodegenerative disorders are marked by oxidative stress and inflammation that contribute to the disease severity; thus, liposomes, dendrimers, and polymeric NPs encapsulate antioxidants and anti-inflammatory compounds, so they target the areas most affected by the disease. Such sophisticated systems minimize the extension of neuronal deterioration and enhance the lot of such patients. The “theranostic” NPs allow for continuous diagnosis and treatment by containing both diagnostic and therapeutic features. These have created unprecedented opportunities to meet the unmet needs in CNS disorders and may revolutionize the evolution of managing neurodegenerative diseases and innovative neuroimaging procedures in the future.

Supercapacitors (SCs), also known as ultracapacitors or electrochemical capacitors, have attracted significant attention as promising energy storage devices due to their superior power density, rapid charge-discharge capability, and long cycle life. This review comprehensively discusses the recent advancements in supercapacitor technology, focusing on the development of novel electrode materials, electrolytes, device designs, and fabrication methods. Particular emphasis is placed on carbon-based materials, metal oxides, conducting polymers, and their hybrid composites, which have shown remarkable improvements in specific capacitance and stability. Additionally, the role of advanced electrolytes, including ionic liquids and gel polymer electrolytes, in enhancing the energy and power density of SCs is explored. The integration of hybrid supercapacitor systems, combining EDLCs and pseudocapacitors, is also highlighted for their potential to overcome the limitations of conventional capacitors and batteries. This review aims to provide valuable insights into the current progress, emerging trends, and future directions for improving the performance and practical applicability of supercapacitors in real-world energy storage applications.

Sweeping contact with cancer continues to rise globally, which has led to advanced research on new treatment approaches; nanotechnology has become crucial to targeted cancer therapy. Within the intimate of nanomaterials, Au/Ag nanostructures have emerged as highly attractive because of their distinctive desirable characteristics and their prospective roles in diagnosis as well as cancer therapy. The nanostructures developed revealed remarkable biocompatibility, optically recursive alteration, and magnificently improved therapeutic effects of gold and silver in conjunction with each other. This review addresses the molecular and systemic aspects of Au/Ag nanostructures in cancer research, including the impact of nanostructures on the molecular genetic pathways and their use of systemic administration in the human organism. We explain some of the related mechanisms of action, such as photothermal therapy (PTT), and photodynamic therapy (PDT), as well as the drug delivery systems where they display potential benefits towards offering a more targeted treatment approach with fewer side effects. The latest development has shown that they have the prospect of real-time imaging and biomarker identification, and owing to this they are being viewed as a tool for individualized treatment. However, there are still some limitations: challenges of scaling up, biological safety, and bringing it to the clinic. It is therefore incumbent upon these managements to overcome these hurdles to optimize for their impact. As a result, the current findings are briefly reviewed, and the development directions are discussed to support the revolutionary role of Au/Ag nanostructures in cancer research and therapy.